文献速递心律失常

持续房颤脉冲场消融联合连续心电监测随访:ADVANTAGE AF 2期研究

Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2.
PubMed 文献 · Circulation · 2025-04-24

ADVANTAGE AF 2期单臂研究纳入255例持续房颤患者,行脉冲场消融(PVI+后壁消融,部分加三尖瓣峡部消融),用植入式心电监测仪连续监测1年。模拟传统监测的无房性心律失常生存率为73.4%,不良事件率2.4%,均达预设终点;详细连续监测显示无≥30秒房性心律失常仅52.0%,但94.0%患者无超过24小时的发作。

要点

  • 持续房颤PVI+后壁消融急性成功率99.6%/100%,模拟监测无房性心律失常73.4%。
  • 三尖瓣峡部消融联合硝酸甘油预防安全有效,双向阻滞率98.6%。
  • 房性心律失常负荷>0.1%或最长发作>1小时与医疗使用增加相关。

核心结论

  • 持续房颤脉冲场消融行PVI+后壁消融安全有效,三尖瓣峡部消融联合硝酸甘油预防安全有效。
  • 房性心律失常负荷<0.1%且发作<1小时与最低医疗使用相关。

研究设计与样本

  • ADVANTAGE AF 2期前瞻性单臂开放标签研究,纳入255例持续房颤患者。
  • 患者行PVI+后壁消融,部分亚组(n=141)加三尖瓣峡部消融,植入式心电监测仪连续随访1年。

主要发现

  • 模拟传统监测的无房性心律失常生存率73.4%,不良事件率2.4%,均达预设终点。
  • 无复发性房扑生存率97.2%;详细连续监测显示无≥30秒房性心律失常52.0%,94.0%患者无超过24小时发作。
  • 三尖瓣峡部消融双向阻滞率98.6%,无ST段改变或室颤并发症。
  • 总手术时间和心房停留时间分别为105±36分钟和59±24分钟。

关键数值与推荐

  • 急性成功率:PVI 99.6%,后壁消融100%。
  • 三尖瓣峡部消融时间8±13分钟,脉冲场应用18±6次,静脉硝酸甘油4±2 mg。
  • 房性心律失常负荷>0.1%和最长发作>1小时预测医疗使用增加。
  • 1年手术有效性:负荷≤0.1%为71.6%,发作<1小时为70.0%。

临床怎么用

  • 持续房颤PFA可考虑PVI联合后壁消融,必要时加三尖瓣峡部消融并预防性使用硝酸甘油。
  • 术后连续监测可评估房性心律失常负荷和发作时长,负荷<0.1%且发作<1小时提示低医疗使用风险。

局限性

  • 单臂开放标签设计,无对照组。
  • 样本量255例,亚组141例,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), in which lesions beyond pulmonary vein isolation (PVI) are often placed. In addition, no large trials have used insertable cardiac monitors for continuous rhythm monitoring after ablation in patients with PerAF or after PFA in any atrial fibrillation population. In Phase 2 of the ADVANTAGE AF study (A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation), patients with PerAF underwent PFA for PVI and posterior wall ablation (PWA) and, in a subcohort, cavotricuspid isthmus ablation for typical atrial flutter. METHODS: Patients with PerAF underwent PVI and posterior wall ablation with the pentaspline PFA catheter and cavotricuspid isthmus with a novel focal-linear PFA catheter after intravenous nitroglycerin prophylaxis. Patients were followed up for 1 year with continuous rhythm monitoring after ablation with insertable cardiac monitors to emulate traditional intermittent monitoring for the primary efficacy end point and to examine atrial arrhythmia (AA) burden and episode duration. RESULTS: This 255-patient cohort (age, 66.7±9.3 years; female, 29%; CHA2DS2-VASc score, 2.4±1.4; body mass index, 30.9±5.3 kg/m2; left atrium diameter, 4.3±0.6 cm) underwent PVI plus posterior wall ablation (99.6%/100% acute success); a subpopulation (n=141; 55.3%) also received cavotricuspid isthmus PFA, with 98.6% achieving bidirectional block without complications (ST-segment changes, ventricular fibrillation). Cavotricuspid isthmus ablation took 8±13 minutes, using 18±6 pulsed field applications and 4±2 mg IV nitroglycerin. The total procedure and atrial dwell times were 105±36 and 59±24 minutes, respectively. Mimicking traditional monitoring, freedom from AA was 73.4% with adverse events in 2.4%, both meeting prespecified end-point criteria. Freedom from recurrent atrial flutter was 97.2%. Detailed analysis of the full insertable cardiac monitor data revealed freedom from AA of ≥30 seconds in 52.0%, and no episode exceeded 24 hours in 94.0% of this PerAF cohort. Both an AA burden >0.1% and longest episode duration >1 hour were predictive of increased health care use. One-year procedural effectiveness was 71.6% and 70.0% using the thresholds of ≤0.1% burden and <1 hour duration, respectively. CONCLUSIONS: In Phase 2 of ADVANTAGE AF, the first multicenter PerAF study of PFA with continuous rhythm monitoring: (1) cavotricuspid isthmus ablation with nitroglycerin prophylaxis was safe and effective, (2) PVI plus posterior wall ablation was safe and effective, and (3) an AA burden <0.1% and AA episode <1 hour duration were end points associated with the lowest health care use. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05443594.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Reddy VY, Gerstenfeld EP, Schmidt B, et al. Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2. Circulation. 2025. PMID: 40273320. doi:10.1161/CIRCULATIONAHA.125.074485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。